查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988495

慢性难治性咳嗽市场：2026-2032年全球市场预测（按药物类别、给药途径、最终用户和分销管道划分）

Chronic Refractory Cough Market by Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，慢性难治性咳嗽市场价值将达到 62.3 亿美元，到 2026 年将成长至 66.1 亿美元，到 2032 年将达到 94.5 亿美元，年复合成长率为 6.12%。

主要市场统计数据
基准年 2025 62.3亿美元
预计年份：2026年 66.1亿美元
预测年份 2032 94.5亿美元
复合年增长率 (%) 6.12%

对慢性难治性咳嗽进行简明扼要、以证据为基础的概述，重点关注诊断的复杂性、治疗的挑战以及相关人员面临的新兴关键问题。

慢性难治性咳嗽是一种复杂的疾病，其特征是症状持续存在、诊断模糊不清以及存在大量未被满足的需求。患有此病的患者往往面临长期疾病，且标准治疗方法不佳，因此亟需创新治疗方法和协作式临床方法。近年来，我们对神经病变机制和气道高敏感性的认识不断加深，这正促使人们重新认识这种疾病，将其视为基于机制的新治疗方法的目标，而不仅仅是对症治疗。

展望未来，概述科学突破、证据进展和经营模式变革如何重塑治疗开发和医疗保健服务。

慢性难治性咳嗽领域正经历多项变革，其驱动力包括机制科学的进步、临床试验设计的创新以及不断发展的医疗服务模式。对介导咳嗽高敏感性的神经通路进行的转化研究，正加速人们对调节感觉信号传导的靶分子的兴趣，并推动治疗策略从广泛的神经调控转向选择性拮抗剂，旨在减少病理性咳嗽的同时维持保护性气道反射。

对新关税政策将如何影响整个治疗价值链的供应链、临床试验物流和商业性准入策略进行营运和策略评估。

影响关税和贸易的政策变化可能会对难治性慢性咳嗽的治疗生态系统产生重大影响，因为它会改变药物研发和商业化过程中关键投入品的成本和稳定供应。 2025年生效的关税措施将影响医药中间体、活性成分和特殊成分，并改变采购、生产和库存管理的标准。依赖跨国供应链的公司可能会面临更高的收货成本和更大的交货波动，这可能迫使采购团队考虑双重采购，并重新审查与受影响地区供应商的合约条款。

从详细的细分观点药物类别、给药途径、通路和最终用户趋势与实际的开发和商业化选择联繫起来。

针对难治性慢性咳嗽的多样化临床和商业性特征，采取细分市场主导的策略至关重要，这需要研发、临床开发和市场准入计画的精心协调。依药物类别划分，市场研究涵盖调变器、鸦片受体拮抗剂和P2X3受体拮抗剂，每种药物的作用机制、安全性特征和差异化途径各不相同。研发团队必须仔细考虑标靶选择性、不利事件管理以及相对于现有对症疗法的定位。依给药途径划分，市场细分为吸入剂、注射剂和口服剂型。剂型的选择会影响製剂的复杂性、药物顺从性以及门诊和急诊护理机构所需的给药基础设施。按分销管道划分，市场细分为医院药房、线上药房和零售药房。通路趋势决定了临床环境中的药物可近性，进而影响库存管理、报销政策以及治疗的启动和持续性。根据最终用户，市场被细分为居家医疗、医院和专科诊所，而对最终用户工作流程的适用性则体现在病患教育、监测策略以及与相关医疗保健专业人员的合作上。

对影响全球主要市场准入和采用的监管、临床研究、生产和报销因素进行区域比较分析。

在难治性慢性咳嗽领域，地理因素对临床开发、监管合作、生产策略和支付方参与度均有显着影响。在美洲，完善的法律规范和先进的临床试验基础设施支持快速招募患者并儘早采用新治疗方法；然而，支付方的严格审查和多样化的保险体係要求提供清晰的价值提案和卫生经济学证据。欧洲、中东和非洲（EMEA）地区的监管和报销环境复杂多样，其特征是集中核准系统和各国之间不同的准入水准。对申请进行策略性优先排序和进行本地化的医疗技术评估对于优化该地区的推广至关重要。亚太地区拥有强大的生产能力、不断扩展的临床研究能力以及波动较大的监管週期。成本压力和多样化的医疗服务模式要求采用高度灵活的商业化策略，并充分考虑当地的临床指南和患者准入机制。

对产业内各公司所做的策略选择进行分析，重点在于创新伙伴关係、商业化能力以及推动成功的竞争因素。

针对难治性慢性咳嗽，各公司的策略越来越重视在科学差异化和实际商业化能力之间取得平衡。新兴生物技术公司专注于选择性感觉受体拮抗剂等新型作用机制，通常致力于建构概念验证（PoC）试验和安全性资料集，从而透过与大型公司合作，实现后期研发和全球市场上市。同时，大型製药企业通常会利用其成熟的商业基础设施、与支付方合作的经验以及生产规模，在临床疗效得到证实后加速产品分销。

旨在加速发展、确保可及性并在快速发展的治疗领域建立可持续竞争优势的具体策略重点和跨职能措施。

致力于拓展慢性难治性咳嗽治疗方案并取得商业性成功的产业领导者应优先考虑以下几项策略性措施。首先，将药物研发与基于机制的临床终点相结合，并建立令人信服的安全性和耐受性论证，以支持真实世界的临床应用。其次，儘早与监管机构和支付方进行持续对话，共同製定符合核准和报销预期的证据方案。第三，透过采购管道多元化、选择区域性生产合作伙伴以及製定紧急时应对计画来增强供应链韧性，从而减轻政策干扰的影响。

为确保可靠性和可操作性，我们采用透明的混合方法研究框架，整合临床专家见解、已发表的证据和营运分析。

本研究采用混合方法，交叉检验了与难治性慢性咳嗽相关的临床发现、实际情况和相关人员的期望。主要调查包括对呼吸内科、耳鼻喉科和基层医疗的关键意见领袖（KOL）进行定性访谈，以及与临床试验研究者、供应链高管和支付方代表进行讨论，以收集关于临床需求和商业化障碍的多方面观点。次要调查则利用同行评审文献、监管指导文件、临床试验註册数据和公开的企业资讯披露，提供循证分析。

简明扼要地整合了临床机会和策略挑战，提出了从科学发现到持续改善病患和系统性结果的路径。

儘管持续性咳嗽且对标准治疗方法无效仍然是一项重大的临床挑战，但近期科学、监管和商业领域的转变正为改善患者预后指明清晰的道路。以机制为导向的治疗方法，结合以患者为中心的终点指标和更完善的真实世界数据（REW）收集，有望彻底改变患者的治疗方式。成功取决于研发、监管、供应链韧性以及支付方基于实证医学的策略等方面的协作执行。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 慢性顽固性咳嗽市场：依药物类别划分

  • 神经调节药物
  • 阿片拮抗剂
  • P2X3拮抗剂

第九章 慢性顽固性咳嗽市场：依给药途径划分

  • 吸入
  • 注射药物
  • 口服

第十章：慢性顽固性咳嗽市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十一章：慢性顽固性咳嗽市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 慢性顽固性咳嗽市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 慢性顽固性咳嗽市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 慢性顽固性咳嗽市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国慢性顽固性咳嗽市场

第十六章 中国慢性顽固性咳嗽市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare Inc.
  • Alitair Pharmaceuticals
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd
  • Bausch Health
  • Bayer AG
  • Cipla Inc.
  • Dr Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Mylan NV by Viatris Inc.
  • NeRRe Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sienna Biotec
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd. by Ipca Labs
  • Zydus Pharmaceuticals USA Inc.
Product Code: MRR-9A2BA9536664

The Chronic Refractory Cough Market was valued at USD 6.23 billion in 2025 and is projected to grow to USD 6.61 billion in 2026, with a CAGR of 6.12%, reaching USD 9.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.23 billion
Estimated Year [2026] USD 6.61 billion
Forecast Year [2032] USD 9.45 billion
CAGR (%) 6.12%

A concise and clinically grounded overview of chronic refractory cough highlighting diagnostic complexity, therapeutic gaps, and emerging imperatives for stakeholders

Chronic refractory cough represents a complex intersection of persistent symptoms, diagnostic ambiguity, and significant unmet clinical needs. Patients living with this condition often experience prolonged morbidity that resists standard interventions, creating a demand for therapeutic innovation and coordinated clinical approaches. Recent advances in understanding neuropathic mechanisms and airway sensory hypersensitivity have reframed the condition as a target for novel mechanism-based therapies rather than purely symptomatic care.

Clinicians increasingly recognize the importance of multidisciplinary assessment, integrating pulmonology, otolaryngology, and neurology perspectives to refine diagnosis and optimize treatment paths. At the same time, payers and health systems are focusing on value-driven outcomes that prioritize measurable symptom reduction and improvements in quality of life. Consequently, evidence generation now must balance rigorous randomized controlled trial design with real-world effectiveness measures that resonate with prescribers, patients, and reimbursement bodies.

As the field evolves, stakeholders must navigate a transitioning landscape where scientific innovation, regulatory scrutiny, and patient-centered care converge. This introduction frames the subsequent analysis, highlighting how scientific breakthroughs, delivery modalities, distribution channels, and regional dynamics interplay to shape strategic priorities for drug developers, clinicians, and health system leaders.

A forward-looking synthesis of scientific breakthroughs, evidence evolution, and commercial model changes that are reshaping therapeutic development and care delivery

The landscape for chronic refractory cough is undergoing several transformative shifts driven by mechanistic science, trial design innovation, and evolving care delivery models. Translational research into the neural pathways that mediate cough hypersensitivity has accelerated interest in targeted molecules that modulate sensory signaling, prompting a shift away from broad neuromodulation toward selective antagonists that aim to preserve protective airway reflexes while reducing pathological cough.

Concurrently, clinical development is incorporating more patient-centric endpoints, including cough frequency monitoring with validated digital devices and patient-reported outcome measures that capture functional impact. This emphasis on real-world, functionally relevant endpoints is promoting closer engagement between clinical investigators, regulatory reviewers, and payer stakeholders to align evidence expectations earlier in development.

At the same time, commercial and operational practices are changing. Digital health solutions and remote monitoring are facilitating decentralized trial components and post-marketing evidence collection, while novel value demonstration approaches are informing payer discussions. Supply chain resilience, partnership models between biotech and larger commercial partners, and an increased appetite for adaptive regulatory pathways are further shaping how innovations move from bench to bedside. Together, these shifts are creating opportunities for differentiated clinical value and for stakeholders who can effectively align science, evidence generation, and commercial execution.

An operational and strategic assessment of how new tariff policies influence supply chains, trial logistics, and commercial access strategies across the therapeutic value chain

Policy changes affecting tariffs and trade can materially influence the chronic refractory cough ecosystem by altering the cost and security of critical inputs used throughout drug development and commercialization. Tariff actions enacted in 2025 that affect pharmaceutical intermediates, active pharmaceutical ingredients, and specialty components shift the calculus for sourcing, manufacturing, and inventory management. Companies reliant on cross-border supply chains may face higher landed costs and greater timing variability, prompting procurement teams to evaluate dual sourcing and to reassess contract terms with suppliers in affected jurisdictions.

Operationally, higher import costs tend to spur efforts to localize production of high-value intermediates and finished dosage forms, which introduces near-term capital and qualification needs but can reduce exposure to future policy volatility. Clinical programs can be affected as well; trials that depend on imported investigational product or comparator agents may experience distribution delays that require contingency planning and expanded communication with study sites and regulators. In response, project teams often accelerate inventory buffers for critical components and engage in scenario planning that quantifies potential disruptions without relying on speculative financial projections.

From a commercial standpoint, pricing negotiation and access strategies may require recalibration. Payers and health systems will expect clear documentation of cost drivers and value delivered, especially when input costs change. Companies can mitigate adverse impacts by investing in supply chain transparency, negotiating long-term procurement agreements that include protections against tariff shifts, and exploring regional manufacturing partnerships to maintain continuity of supply. Ultimately, navigating tariff-related dynamics in 2025 demands a coordinated response across sourcing, regulatory, clinical operations, and commercial functions to preserve program momentum and patient access.

A detailed segmentation-driven perspective that links drug class, delivery modality, distribution pathways, and end-user dynamics to practical development and commercialization choices

Segment-driven strategies are central to addressing the heterogeneous clinical and commercial contours of chronic refractory cough, and they require granular alignment of R&D, clinical development, and market entry plans. Based on Drug Class, the market is studied across Neuromodulators, Opioid Antagonists, and P2X3 Antagonists, each representing distinct mechanisms, safety profiles, and differentiation pathways; development teams must weigh target selectivity, adverse event management, and positioning against existing symptomatic therapies. Based on Route Of Administration, the market is studied across Inhalation, Injectable, and Oral, and modality decisions influence formulation complexity, adherence considerations, and the infrastructure needed for delivery in outpatient and acute care settings. Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, and channel dynamics determine stocking, reimbursement practices, and point-of-care accessibility that affect uptake and continuity of treatment. Based on End User, the market is studied across Homecare, Hospitals, and Specialty Clinics, and alignment to end-user workflows informs patient education, monitoring strategies, and collaboration with allied health providers.

Taken together, these segmentation lenses reveal actionable implications for product development and commercialization. Drug class selection should be informed by a trade-off between efficacy on mechanistic endpoints and tolerability in broad patient populations. Route-of-administration decisions must reconcile clinical advantages with manufacturing feasibility and patient preferences. Distribution strategies should be tailored to where prescribing decisions are made and where adherence support can be most effectively delivered. End-user segmentation requires investments in clinician education and post-prescription support to ensure that therapeutic benefits translate into sustained real-world outcomes.

A comparative regional analysis of regulatory, clinical research, manufacturing, and reimbursement factors shaping access and adoption across major global markets

Geographic dynamics materially influence clinical development, regulatory interactions, manufacturing strategies, and payer engagement across the chronic refractory cough landscape. In the Americas, regulatory frameworks and advanced clinical trial infrastructures support rapid patient recruitment and early adoption of novel therapies, while payer scrutiny and diverse insurance structures require clear value propositions and health-economic evidence. Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement environment where centralized approvals coexist with country-level access variability; strategic sequencing of submissions and localized health technology assessments are essential to optimize regional uptake. Asia-Pacific features strong manufacturing capacity, growing clinical research capabilities, and variable regulatory timelines; cost pressures and diverse healthcare delivery models necessitate adaptable commercialization approaches that account for local clinical guidelines and patient access mechanisms.

Regional considerations also shape supply chain choices and partnership models. Proximity to manufacturing hubs, availability of skilled contract development and manufacturing organizations, and logistical infrastructure influence decisions on where to site production of active ingredients and finished products. Moreover, patient-reported symptom burden, prevalence of comorbidities, and care-seeking behaviors vary by region, affecting the design of clinical trials and the messaging used to engage prescribers and patients. A nuanced regional strategy that aligns evidence generation, regulatory sequencing, and commercial execution will be critical for translating clinical innovation into sustained therapeutic impact across global markets.

An analysis of industry players' strategic choices highlighting innovation partnerships, commercialization capabilities, and competitive differentiation factors driving success

Company strategies in chronic refractory cough increasingly reflect a balance between scientific differentiation and pragmatic commercialization capabilities. Emerging biotechs focused on novel mechanisms such as selective sensory antagonists often concentrate on proof-of-concept studies and building safety dossiers that enable partnering with larger firms for late-stage development and global launches. Larger pharmaceutical companies typically leverage established commercial infrastructures, payer engagement experience, and manufacturing scale to accelerate adoption once clinical benefits are demonstrated.

Partnerships and alliances are becoming central to advancing promising candidates, with collaboration models that include co-development, licensing, and targeted acquisitions to complement internal capabilities. Contract research organizations, specialty contract manufacturers, and digital health vendors provide modular solutions that enable sponsors to scale trials, optimize formulations, and capture real-world evidence. Competitive differentiation hinges not only on clinical efficacy but also on tolerability profiles, ease of administration, and the ability to demonstrate meaningful improvements in patient-reported outcomes. Companies that integrate robust safety monitoring, patient support programs, and payer-facing health economic data will be better positioned to navigate reimbursement negotiations and achieve sustainable uptake.

Concrete strategic priorities and cross-functional actions designed to accelerate development, ensure access, and build durable competitive advantage in a rapidly evolving therapeutic area

Industry leaders seeking to advance therapeutic options and achieve commercial success in chronic refractory cough should prioritize several strategic actions. First, align drug development with mechanism-based clinical endpoints and build a compelling safety and tolerability narrative that anticipates real-world use. Second, invest in early and continuous engagement with regulatory authorities and payers to co-design evidence packages that meet both approval and reimbursement expectations. Third, strengthen supply chain resilience by diversifying sourcing, qualifying regional manufacturing partners, and incorporating contingency planning to mitigate policy-driven disruptions.

Additionally, incorporate digital monitoring tools and patient-reported outcome measures into trials and post-marketing programs to demonstrate sustained functional benefits. Develop tailored commercialization plans that reflect channel dynamics and end-user needs, ensuring that educational initiatives for specialty clinics and hospitals are paired with adherence support for home-based therapy. Finally, pursue strategic partnerships that accelerate late-stage development, expand geographic reach, and complement internal capabilities, while maintaining a disciplined approach to evidence generation and stakeholder alignment to maximize clinical and commercial impact.

A transparent mixed-methods research framework integrating clinical expert input, published evidence, and operational analysis to ensure credibility and practical relevance

This research employed a mixed-methods approach designed to triangulate clinical insights, operational realities, and stakeholder expectations relevant to chronic refractory cough. Primary research involved qualitative interviews with key opinion leaders in pulmonology, otolaryngology, and primary care, as well as discussions with clinical trial investigators, supply chain executives, and payer representatives to capture multi-perspective inputs on clinical needs and commercialization barriers. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to ground analysis in documented evidence.

Data synthesis combined thematic qualitative analysis with structured evidence mapping to identify convergent trends, differentiation levers, and potential operational risks. Case-level comparisons of development strategies and distribution models were used to derive practical recommendations. Limitations include potential variability in regional regulatory timelines and the evolving nature of clinical evidence, which necessitate periodic updates. To mitigate bias, findings were validated through multiple expert consultations and cross-checked against published clinical outcomes and regulatory communications.

A concise synthesis of clinical opportunities and strategic imperatives that frames the path from scientific discovery to sustained patient and system-level outcomes

Persistent cough that is refractory to standard interventions remains a high-impact clinical challenge, but recent scientific, regulatory, and commercial shifts provide distinct pathways to improved patient outcomes. Mechanism-focused therapeutics, coupled with patient-centric endpoints and enhanced real-world evidence collection, offer the potential to transform care for those affected. Success will depend on coordinated execution across development, regulatory engagement, supply chain resilience, and payer-facing evidence strategies.

Stakeholders who prioritize targeted clinical differentiation, align evidence generation with reimbursement expectations, and design distribution and support models that reflect end-user workflows will be best positioned to translate scientific advances into meaningful patient benefit. As the landscape continues to evolve, ongoing dialogue among clinicians, developers, payers, and operational partners will be essential to deliver sustainable therapeutic progress and improved quality of life for patients living with chronic refractory cough.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Refractory Cough Market, by Drug Class

  • 8.1. Neuromodulators
  • 8.2. Opioid Antagonists
  • 8.3. P2X3 Antagonists

9. Chronic Refractory Cough Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Chronic Refractory Cough Market, by End User

  • 10.1. Homecare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Chronic Refractory Cough Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Chronic Refractory Cough Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chronic Refractory Cough Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chronic Refractory Cough Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chronic Refractory Cough Market

16. China Chronic Refractory Cough Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Inc.
  • 17.6. Alitair Pharmaceuticals
  • 17.7. Amneal Pharmaceuticals Inc.
  • 17.8. Apotex Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Aurobindo Pharma Ltd
  • 17.11. Bausch Health
  • 17.12. Bayer AG
  • 17.13. Cipla Inc.
  • 17.14. Dr Reddy's Laboratories Ltd.
  • 17.15. Glenmark Pharmaceuticals Ltd.
  • 17.16. GSK PLC
  • 17.17. Hikma Pharmaceuticals PLC
  • 17.18. Intas Pharmaceuticals Ltd.
  • 17.19. Mylan N.V. by Viatris Inc.
  • 17.20. NeRRe Therapeutics
  • 17.21. Novartis AG
  • 17.22. Pfizer Inc.
  • 17.23. Sienna Biotec
  • 17.24. Strides Pharma
  • 17.25. Sun Pharmaceutical Industries Ltd
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Torrent Pharmaceuticals Ltd.
  • 17.28. Unichem Laboratories Ltd. by Ipca Labs
  • 17.29. Zydus Pharmaceuticals USA Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY NEUROMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY NEUROMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY NEUROMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY OPIOID ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY OPIOID ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY OPIOID ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY P2X3 ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY P2X3 ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY P2X3 ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. GCC CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. GCC CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GCC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. G7 CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. G7 CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. G7 CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. NATO CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NATO CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NATO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)